Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee

Peggy M. Cawthon; Marjolein Visser; Hidenori Arai; José A. Ávila-Funes; Rocco Barazzoni; Shalender Bhasin; Ellen Binder; Olivier Bruyère; Tommy Cederholm; Liang Kung Chen; Cyrus Cooper; Gustavo Duque; Roger A. Fielding; Jack Guralnik; Douglas P. Kiel; Ben Kirk; Francesco Landi; Avan A. Sayer; Stephan Von Haehling; Jean Woo; Alfonso J. Cruz-Jentoft

doi:10.1007/s41999-022-00706-5

Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee

Peggy M. Cawthon, Marjolein Visser^*, Hidenori Arai, José A. Ávila-Funes, Rocco Barazzoni, Shalender Bhasin, Ellen Binder, Olivier Bruyère, Tommy Cederholm, Liang Kung Chen, Cyrus Cooper, Gustavo Duque, Roger A. Fielding, Jack Guralnik, Douglas P. Kiel, Ben Kirk, Francesco Landi, Avan A. Sayer, Stephan Von Haehling, Jean WooAlfonso J. Cruz-Jentoft

^*Corresponding author for this work

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Methods: The aim of this paper is to define terms commonly related to sarcopenia to enable standardization of these terms in research and clinical settings. The Global Leadership Initiative in Sarcopenia (GLIS) aims to bring together leading investigators in sarcopenia research to develop a single definition that can be utilized worldwide; work on a global definition of sarcopenia is ongoing. The first step of GLIS is to develop the common terminology, or a glossary, that will facilitate agreement on a global definition of sarcopenia as well as interpretation of clinical and research findings. Results: Several terms that are commonly used in sarcopenia research are defined, including self-reported measures of function and ability; objective physical performance tests; and measures related to muscle function and size. Conclusion: As new methods and technologies are developed, these definitions may be expanded or refined over time. Our goal is to promote this common language to describe sarcopenia and its components in clinical and research settings in order to increase clinical awareness and research interest in this important condition. We hope that the use of common terminology in sarcopenia research will increase understanding of the concept and improve communication around this important age-related condition.

Original language	English
Pages (from-to)	1239-1244
Number of pages	6
Journal	European Geriatric Medicine
Volume	13
Issue number	6
Early online date	29 Nov 2022
DOIs	https://doi.org/10.1007/s41999-022-00706-5
Publication status	Published - Dec 2022

Bibliographical note

Funding Information:
Dr. Cruz-Jentoft reports obtaining research funding from AstraZeneca. Dr. Kirk reports consultancy/honorarium fees from the following companies/enterprises that work in the medical and/or musculoskeletal fields: Abbott Nutrition (UK); Academy of Nutrition and Dietetics (USA); AusDoc (Australian Doctor). Dr. Kirk is also supported by a research grant from TSI Pharmaceuticals. Dr. Kiel reports royalties from publication Wolters Kluwer for chapters in UpToDate on Falls; scientific advisory boards for Pfizer, Solarea Bio, Reneo; grants from Amgen and Solarea Bio; Data Safety and Safety Monitoring Board for Agnovos. Dr. Landi reports consultancy and invited lecture to Abbott, Nutricia, ErreKappa, and Professional Dietetics. Dr. Duque reports paid consultancy for TSI, Abbott, and Nutricia. Dr. Bruyère reports to being a shareholder of SARQOL SRL. Dr. Cawthon reports being a consultant to BioAge Labs. Dr. Fielding reports to being a paid consultant for Pfizer, Nestle, Amazentis, Biophytis, Rejuvenate Biomed, Juvicell. Dr. Fielding reports to being on the advisory Board for Inside Tracker and Cytokinetics and reports to being a shareholder of Azcella Health. He has obtained research funding from Lonza. Dr. Bhasin reports consultancy fees from OPKO Health and Aditum Bio. He has obtained research funding from AbbVie and Metro International BioTech. Dr. Von Haehling reports being a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, Boehringer Ingelheim, BRAHMS, Chugai, Grünenthal, Helsinn, Hexal, Novartis, Pharmacosmos, Respicardia, Roche, Servier, Sorin, and Vifor. Dr. Cederholm reports providing paid lectures arranged by medical nutrition companies. Dr. Binder reports consulting income from Eisai, Inc. Drs. Sayer, Cooper, Arai, Guralnik, Woo, Ávila-Funes, Chen, Visser, Barazzoni report no current personal financial interests.

Publisher Copyright:
© 2022, The Author(s).

Funding

Dr. Cruz-Jentoft reports obtaining research funding from AstraZeneca. Dr. Kirk reports consultancy/honorarium fees from the following companies/enterprises that work in the medical and/or musculoskeletal fields: Abbott Nutrition (UK); Academy of Nutrition and Dietetics (USA); AusDoc (Australian Doctor). Dr. Kirk is also supported by a research grant from TSI Pharmaceuticals. Dr. Kiel reports royalties from publication Wolters Kluwer for chapters in UpToDate on Falls; scientific advisory boards for Pfizer, Solarea Bio, Reneo; grants from Amgen and Solarea Bio; Data Safety and Safety Monitoring Board for Agnovos. Dr. Landi reports consultancy and invited lecture to Abbott, Nutricia, ErreKappa, and Professional Dietetics. Dr. Duque reports paid consultancy for TSI, Abbott, and Nutricia. Dr. Bruyère reports to being a shareholder of SARQOL SRL. Dr. Cawthon reports being a consultant to BioAge Labs. Dr. Fielding reports to being a paid consultant for Pfizer, Nestle, Amazentis, Biophytis, Rejuvenate Biomed, Juvicell. Dr. Fielding reports to being on the advisory Board for Inside Tracker and Cytokinetics and reports to being a shareholder of Azcella Health. He has obtained research funding from Lonza. Dr. Bhasin reports consultancy fees from OPKO Health and Aditum Bio. He has obtained research funding from AbbVie and Metro International BioTech. Dr. Von Haehling reports being a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, Boehringer Ingelheim, BRAHMS, Chugai, Grünenthal, Helsinn, Hexal, Novartis, Pharmacosmos, Respicardia, Roche, Servier, Sorin, and Vifor. Dr. Cederholm reports providing paid lectures arranged by medical nutrition companies. Dr. Binder reports consulting income from Eisai, Inc. Drs. Sayer, Cooper, Arai, Guralnik, Woo, Ávila-Funes, Chen, Visser, Barazzoni report no current personal financial interests.

Funders	Funder number
AstraZeneca
TSI Pharmaceuticals
Japan Society for the Promotion of Science	21H02834

Keywords

GLIS
Sarcopenia
Standardization
Terminology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s41999-022-00706-5

Persistent URL (handle)

Persistent link

Cite this

Cawthon, P. M., Visser, M., Arai, H., Ávila-Funes, J. A., Barazzoni, R., Bhasin, S., Binder, E., Bruyère, O., Cederholm, T., Chen, L. K., Cooper, C., Duque, G., Fielding, R. A., Guralnik, J., Kiel, D. P., Kirk, B., Landi, F., Sayer, A. A., Von Haehling, S., ... Cruz-Jentoft, A. J. (2022). Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee. European Geriatric Medicine, 13(6), 1239-1244. https://doi.org/10.1007/s41999-022-00706-5

@article{ea8e3e0837cd4894a4b63a4c897d0752,

title = "Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee",

abstract = "Methods: The aim of this paper is to define terms commonly related to sarcopenia to enable standardization of these terms in research and clinical settings. The Global Leadership Initiative in Sarcopenia (GLIS) aims to bring together leading investigators in sarcopenia research to develop a single definition that can be utilized worldwide; work on a global definition of sarcopenia is ongoing. The first step of GLIS is to develop the common terminology, or a glossary, that will facilitate agreement on a global definition of sarcopenia as well as interpretation of clinical and research findings. Results: Several terms that are commonly used in sarcopenia research are defined, including self-reported measures of function and ability; objective physical performance tests; and measures related to muscle function and size. Conclusion: As new methods and technologies are developed, these definitions may be expanded or refined over time. Our goal is to promote this common language to describe sarcopenia and its components in clinical and research settings in order to increase clinical awareness and research interest in this important condition. We hope that the use of common terminology in sarcopenia research will increase understanding of the concept and improve communication around this important age-related condition.",

keywords = "GLIS, Sarcopenia, Standardization, Terminology",

author = "Cawthon, {Peggy M.} and Marjolein Visser and Hidenori Arai and {\'A}vila-Funes, {Jos{\'e} A.} and Rocco Barazzoni and Shalender Bhasin and Ellen Binder and Olivier Bruy{\`e}re and Tommy Cederholm and Chen, {Liang Kung} and Cyrus Cooper and Gustavo Duque and Fielding, {Roger A.} and Jack Guralnik and Kiel, {Douglas P.} and Ben Kirk and Francesco Landi and Sayer, {Avan A.} and {Von Haehling}, Stephan and Jean Woo and Cruz-Jentoft, {Alfonso J.}",

note = "Funding Information: Dr. Cruz-Jentoft reports obtaining research funding from AstraZeneca. Dr. Kirk reports consultancy/honorarium fees from the following companies/enterprises that work in the medical and/or musculoskeletal fields: Abbott Nutrition (UK); Academy of Nutrition and Dietetics (USA); AusDoc (Australian Doctor). Dr. Kirk is also supported by a research grant from TSI Pharmaceuticals. Dr. Kiel reports royalties from publication Wolters Kluwer for chapters in UpToDate on Falls; scientific advisory boards for Pfizer, Solarea Bio, Reneo; grants from Amgen and Solarea Bio; Data Safety and Safety Monitoring Board for Agnovos. Dr. Landi reports consultancy and invited lecture to Abbott, Nutricia, ErreKappa, and Professional Dietetics. Dr. Duque reports paid consultancy for TSI, Abbott, and Nutricia. Dr. Bruy{\`e}re reports to being a shareholder of SARQOL SRL. Dr. Cawthon reports being a consultant to BioAge Labs. Dr. Fielding reports to being a paid consultant for Pfizer, Nestle, Amazentis, Biophytis, Rejuvenate Biomed, Juvicell. Dr. Fielding reports to being on the advisory Board for Inside Tracker and Cytokinetics and reports to being a shareholder of Azcella Health. He has obtained research funding from Lonza. Dr. Bhasin reports consultancy fees from OPKO Health and Aditum Bio. He has obtained research funding from AbbVie and Metro International BioTech. Dr. Von Haehling reports being a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, Boehringer Ingelheim, BRAHMS, Chugai, Gr{\"u}nenthal, Helsinn, Hexal, Novartis, Pharmacosmos, Respicardia, Roche, Servier, Sorin, and Vifor. Dr. Cederholm reports providing paid lectures arranged by medical nutrition companies. Dr. Binder reports consulting income from Eisai, Inc. Drs. Sayer, Cooper, Arai, Guralnik, Woo, {\'A}vila-Funes, Chen, Visser, Barazzoni report no current personal financial interests. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1007/s41999-022-00706-5",

language = "English",

volume = "13",

pages = "1239--1244",

journal = "European Geriatric Medicine",

issn = "1878-7649",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "6",

}

Cawthon, PM, Visser, M, Arai, H, Ávila-Funes, JA, Barazzoni, R, Bhasin, S, Binder, E, Bruyère, O, Cederholm, T, Chen, LK, Cooper, C, Duque, G, Fielding, RA, Guralnik, J, Kiel, DP, Kirk, B, Landi, F, Sayer, AA, Von Haehling, S, Woo, J & Cruz-Jentoft, AJ 2022, 'Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee', European Geriatric Medicine, vol. 13, no. 6, pp. 1239-1244. https://doi.org/10.1007/s41999-022-00706-5

TY - JOUR

T1 - Defining terms commonly used in sarcopenia research

T2 - a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee

AU - Cawthon, Peggy M.

AU - Visser, Marjolein

AU - Arai, Hidenori

AU - Ávila-Funes, José A.

AU - Barazzoni, Rocco

AU - Bhasin, Shalender

AU - Binder, Ellen

AU - Bruyère, Olivier

AU - Cederholm, Tommy

AU - Chen, Liang Kung

AU - Cooper, Cyrus

AU - Duque, Gustavo

AU - Fielding, Roger A.

AU - Guralnik, Jack

AU - Kiel, Douglas P.

AU - Kirk, Ben

AU - Landi, Francesco

AU - Sayer, Avan A.

AU - Von Haehling, Stephan

AU - Woo, Jean

AU - Cruz-Jentoft, Alfonso J.

N1 - Funding Information: Dr. Cruz-Jentoft reports obtaining research funding from AstraZeneca. Dr. Kirk reports consultancy/honorarium fees from the following companies/enterprises that work in the medical and/or musculoskeletal fields: Abbott Nutrition (UK); Academy of Nutrition and Dietetics (USA); AusDoc (Australian Doctor). Dr. Kirk is also supported by a research grant from TSI Pharmaceuticals. Dr. Kiel reports royalties from publication Wolters Kluwer for chapters in UpToDate on Falls; scientific advisory boards for Pfizer, Solarea Bio, Reneo; grants from Amgen and Solarea Bio; Data Safety and Safety Monitoring Board for Agnovos. Dr. Landi reports consultancy and invited lecture to Abbott, Nutricia, ErreKappa, and Professional Dietetics. Dr. Duque reports paid consultancy for TSI, Abbott, and Nutricia. Dr. Bruyère reports to being a shareholder of SARQOL SRL. Dr. Cawthon reports being a consultant to BioAge Labs. Dr. Fielding reports to being a paid consultant for Pfizer, Nestle, Amazentis, Biophytis, Rejuvenate Biomed, Juvicell. Dr. Fielding reports to being on the advisory Board for Inside Tracker and Cytokinetics and reports to being a shareholder of Azcella Health. He has obtained research funding from Lonza. Dr. Bhasin reports consultancy fees from OPKO Health and Aditum Bio. He has obtained research funding from AbbVie and Metro International BioTech. Dr. Von Haehling reports being a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, Boehringer Ingelheim, BRAHMS, Chugai, Grünenthal, Helsinn, Hexal, Novartis, Pharmacosmos, Respicardia, Roche, Servier, Sorin, and Vifor. Dr. Cederholm reports providing paid lectures arranged by medical nutrition companies. Dr. Binder reports consulting income from Eisai, Inc. Drs. Sayer, Cooper, Arai, Guralnik, Woo, Ávila-Funes, Chen, Visser, Barazzoni report no current personal financial interests. Publisher Copyright: © 2022, The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - Methods: The aim of this paper is to define terms commonly related to sarcopenia to enable standardization of these terms in research and clinical settings. The Global Leadership Initiative in Sarcopenia (GLIS) aims to bring together leading investigators in sarcopenia research to develop a single definition that can be utilized worldwide; work on a global definition of sarcopenia is ongoing. The first step of GLIS is to develop the common terminology, or a glossary, that will facilitate agreement on a global definition of sarcopenia as well as interpretation of clinical and research findings. Results: Several terms that are commonly used in sarcopenia research are defined, including self-reported measures of function and ability; objective physical performance tests; and measures related to muscle function and size. Conclusion: As new methods and technologies are developed, these definitions may be expanded or refined over time. Our goal is to promote this common language to describe sarcopenia and its components in clinical and research settings in order to increase clinical awareness and research interest in this important condition. We hope that the use of common terminology in sarcopenia research will increase understanding of the concept and improve communication around this important age-related condition.

AB - Methods: The aim of this paper is to define terms commonly related to sarcopenia to enable standardization of these terms in research and clinical settings. The Global Leadership Initiative in Sarcopenia (GLIS) aims to bring together leading investigators in sarcopenia research to develop a single definition that can be utilized worldwide; work on a global definition of sarcopenia is ongoing. The first step of GLIS is to develop the common terminology, or a glossary, that will facilitate agreement on a global definition of sarcopenia as well as interpretation of clinical and research findings. Results: Several terms that are commonly used in sarcopenia research are defined, including self-reported measures of function and ability; objective physical performance tests; and measures related to muscle function and size. Conclusion: As new methods and technologies are developed, these definitions may be expanded or refined over time. Our goal is to promote this common language to describe sarcopenia and its components in clinical and research settings in order to increase clinical awareness and research interest in this important condition. We hope that the use of common terminology in sarcopenia research will increase understanding of the concept and improve communication around this important age-related condition.

KW - GLIS

KW - Sarcopenia

KW - Standardization

KW - Terminology

UR - http://www.scopus.com/inward/record.url?scp=85142921230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142921230&partnerID=8YFLogxK

U2 - 10.1007/s41999-022-00706-5

DO - 10.1007/s41999-022-00706-5

M3 - Article

C2 - 36445639

AN - SCOPUS:85142921230

SN - 1878-7649

VL - 13

SP - 1239

EP - 1244

JO - European Geriatric Medicine

JF - European Geriatric Medicine

IS - 6

ER -

Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this